This free survey is powered by
  1. Surveys
  2. 2015
  3. December
  4. N
  5. Neoadjuvant Chemotherapy Resectable Pancreatic Ca
0%
Exit Survey
 
Contact Information
First Name : 
Last Name : 
Institution : 
Address  : 
City : 
State : 
Zip : 
Email Address : 
 
 
 
Expert Background / Years in Practice
 
<5
 
5-10
 
10-20
 
20+
 
 
 
Annual Case Volume
 
<10
 
10-30
 
31-50
 
50+
 
 
 
Which best describes your current management of resectable pancreatic head adenocarcinoma?
 
Upfront surgery alone
 
Upfront surgery -> adjuvant chemotherapy
 
Upfront surgery -> adjuvant chemoradiation
 
Neoadjuvant chemotherapy -> surgery alone
 
Neoadjuvant chemoradiation-> surgery alone
 
Neoadjuvant chemoradiation -> surgery -> adjuvant chemoradiation
 
Other
 
 
 
 
When you counsel patients about pancreaticoduodenectomy, with what proportion do you discuss neoadjuvant chemotherapy?”
 
0
 
< 25%
 
25-50%
 
50-75%
 
> 75%
 
 
 
What proportion of your patients undergoing pancreaticoduodenectomy have received neoadjuvant chemotherapy?
 
< 25%
 
25-50%
 
50-75%
 
> 75%
 
 
 
Which would be your preferred neoadjuvant therapeutic agent(s)?
 
Gemcitabine alone
 
Gemcitabine + platinum-based
 
Gemcitabine + 5-FU
 
Gemcitabine + radiation
 
Other
 

 
 
 
What are your major concerns about recommending neoadjuvant chemotherapy for resectable disease?
 
Age and comorbidities
 
Delay in surgery
 
Unclear benefit
 
Prolonged diagnosis and referral
 
Adjuvant therapy better selects patients
 
Treatment toxicity
 
Risk of surgical complications
 
Other
 

 
 
How interested would you be in collaborating in a multi-centre randomized trial of neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma?
Very Uninterested Not Interested Neutral Interested Very Interested
 
 
 
 
Comments/Suggestions: